BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:XS-411 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of XS-411\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07080775-1737@assetmemo.bio
DTSTAMP:20261121T005736Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:XS-411: Phase 1/2 readout est. (NCT07080775)
DESCRIPTION:XS-411\, phase 1/2\, Parkinson's Disease.\nStudy: The Safety\,T
 olerability\, Efficacy of XS411 Cell Injection for the Treatment of Primar
 y Parkinson's Disease\nEstimated primary completion: July 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/xs-411#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07080775
URL:https://assetmemo.bio/drug/xs-411#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07166757-1737@assetmemo.bio
DTSTAMP:20261121T005736Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:XS-411: Phase 1/2 readout est. (NCT07166757)
DESCRIPTION:XS-411\, phase 1/2\, Parkinson's Disease.\nStudy: Clinical Stud
 y to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease\nEstim
 ated primary completion: 30 March 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/xs-411#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07166757
URL:https://assetmemo.bio/drug/xs-411#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
